AlzeCure's ACD856 Demonstrates Good Tolerability in Phase I Clinical Trial and is Approved for Additional Doses

Author's Avatar
Aug 27, 2021

STOCKHOLM, SWEDEN / ACCESSWIRE / August 27, 2021 / AlzeCure Pharma (STO:ALZCUR, Financial) (FRA:AC6, Financial)